AdMSC
Phase 2Small molecule
AdMSC is one of 66 small molecule programs targeting Scleroderma. It is currently in Phase 2.
2
Indications
4
Total Trials
4
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
58 competitors in Scleroderma
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Influenza Vaccine
NovartisApproved
Rezurock
KKadmon, a Sanofi Company
Approved
Acetylsalicylic Acid
BayerApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Cialis
Eli LillyPhase 3
Ofev
Boehringer IngelheimPhase 3
Viagra
VViatris Specialty LLC
Phase 3
Domperidone
Johnson & JohnsonPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Scleroderma1 trial
Scleroderma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AdMSC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Toulouse